Smith & Nephew plc ADR Dossier
Qualitative Analysis
Business overview
Smith & Nephew plc (LSE: SN, NYSE: SNN) is a leading global medical technology company founded in Hull, UK, in 1856 and currently headquartered in Watford, UK. The company operates through three core global business units: Orthopaedics (encompassing knee and hip implants, trauma & extremities, and robotics), Sports Medicine & ENT (minimally invasive surgical instruments and arthroscopic technologies), and Advanced Wound Management (wound care, bioactives, and negative pressure wound therapy). With approximately 17,000 employees, the company serves healthcare providers in around 100 countries, generating over half of its revenues in the United States. Under the leadership of CEO Deepak Nath, the company is executing its strategic transformation to drive accelerated revenue growth, operational efficiency, and enhanced shareholder returns.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A new strategic framework launched in December 2025 to succeed the 12-Point Plan. RISE focuses on four pillars: REACH (driving adoption of the differentiated portfolio), INNOVATE (accelerating new product launches), SCALE (allocating capital to high-return opportunities), and EXECUTE (driving operational efficiency).
Expected impact: Targets a 6-7% underlying revenue compound annual growth rate (CAGR), 9-10% trading profit CAGR, more than $1 billion in free cash flow, and a 12-13% post-tax ROIC by 2028.
Streamlining the product range to reduce stock holding requirements, lower capital intensity, and migrate customers to the latest technology products.
Expected impact: Expected to reduce gross inventory by approximately $500 million and significantly lower capital requirements.
Targeting the rapidly growing ASC market by offering an expanded enterprise ASC suite—an end-to-end solution enabling customers to finance, design, build, equip, and optimize their centers.
Expected impact: Aims to capture a larger share of the 6%+ CAGR ASC market growth, building on the 40% of CORI surgical systems placed in ASC settings in 2025.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the developer of Tendon Seam™, an innovative rotator cuff repair (RCR) system designed to significantly reduce re-tear rates and improve patient outcomes, strengthening the Sports Medicine shoulder repair business.
Financial impact: Initial cash payment of $225 million with up to $225 million in performance-based payments over five years. Expected to be marginally dilutive to trading profit in 2026, broadly neutral in 2027, and accretive to Group trading profit margin by 2028.
Strategic Partnerships
Brings together best-in-class expertise and technologies into a single, aligned delivery model to support de novo ASC development and modernization of existing facilities.
Terms: Not disclosed